Progressive Supranuclear Palsy (PSP) is also known as Steele-Richardson-Olszewski syndrome, is an uncommon brain disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking.
&nbsp;
Progressive Supranuclear Palsy (PSP) is a rare progressive condition, which can cause issues with balance, movement, vision, speech, and swallowing.
&nbsp;
The condition has been linked to alternations in specific genes, but these genetic faults are not inherited and the risk to other family members with PSP, is very low.&nbsp;
&nbsp;
Although PSP is not fatal, symptoms do continue to worsen, and it can not be cured. Complications that result from worsening symptoms, such as pneumonia&mdash;from breathing in food particles while choking during eating&mdash;can be life-threatening.
&nbsp;
The only proven risk factor for PSP is age. Typically, the condition affects people around the age of 60 and is virtually unknown in people under the age of 40.
&nbsp;
Progressive Supranuclear Palsy Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Progressive Supranuclear Palsy in 7MM from 2019 to 2032 is segmented as:-&nbsp;
&bull; Total Prevalent cases of Progressive Supranuclear Palsy
&bull; Gender-specific Prevalent Cases of PSP
&bull; Phenotype associated with PSP
&bull; Comorbidities associated with PSP
&nbsp;
Progressive Supranuclear Palsy Epidemiology&nbsp;
<ul>
<li>The total prevalent cases of Progressive Supranuclear Palsy in the&nbsp;7MM were ~81K in 2022</li>
<li>The United States accounted for a total of 26% Progressive Supranuclear Palsy prevalent cases</li>
<li>EU4 and the UK accounted for a total of 45% Progressive Supranuclear Palsy prevalent cases</li>
<li>Japan accounted for a total of 29% Progressive Supranuclear Palsy prevalent cases</li>
<li>Around ~50% were accounted by progressive supranuclear palsy with Richardson&rsquo;s syndrome in EU4 and the UK</li>
<li>A total of ~54% of diagnosed cases were contributed by males whereas ~46% of cases were by females</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #0066cc;" href="https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market" target="_blank" rel="noopener noreferrer">Progressive Supranuclear Palsy Market</a>
The therapeutic market of Progressive Supranuclear Palsy in 7MM in 2022 was USD 8.3 billion.
&nbsp;
Progressive Supranuclear Palsy Emerging Drugs
The Emerging drugs of the Progressive Supranuclear Palsy market are&nbsp;
&bull; AZP2006
&bull; UCB0107&nbsp;
&bull; ASN120290
&bull; LMTX
And many others.&nbsp;
&nbsp;
Progressive Supranuclear Palsy Key Players
The key players in the Progressive Supranuclear Palsy market are
&bull; AlzProtect
&bull; UCB Biopharma&nbsp;
&bull; Asceneuron Therapeutics
&bull; TauRx Pharmaceuticals&nbsp;
And many others.&nbsp;

Progressive Supranuclear Palsy Market

Progressive Supranuclear Palsy Infographic

Progressive Supranuclear Palsy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.